Elicio Therapeutics, Inc.ELTX
What Elicio Therapeutics, Inc. does.
We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat sarcoma viral oncogene homolog (“mKRAS”) - positive pancreatic cancer, colorectal cancer (“CRC”), lung cancer and other mKRAS positive cancers. We intend to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Our proprietary Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate robust T cell responses in patients that can potentially translate to meaningful clinical benefit.
We believe the therapeutic utility of currently approved and development stage cancer immunotherapies is limited in many cases due to their inability to sufficiently localize to lymph nodes and adequately engage with the critical immune cells responsible for stimulating adaptive immunity. Our AMP technology is specifically intended to localize payloads to lymph nodes leading to the generation of a robust T cell response that we believe is critical to generate an anticancer immune response.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.9M | $28.3M | $2.3M | — | — | — |
| Net income | -$80.1M | -$54.6M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| Free cash flow | -$22.9M | -$53.0M | -$22.8M | -$32.8M | -$37.2M | -$37.0M |
More on ELTX.
- Elicio Therapeutics, Inc. summary
- Elicio Therapeutics, Inc. financial statements
- Elicio Therapeutics, Inc. key metrics
- Elicio Therapeutics, Inc. health scores and style box
- Elicio Therapeutics, Inc. earnings
- Elicio Therapeutics, Inc. dividends
- Elicio Therapeutics, Inc. valuation
- Elicio Therapeutics, Inc. ownership and insiders
- Elicio Therapeutics, Inc. peers
Figures from Elicio Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.